PC-3M Xenograft Rat Model Service for Prostate Cancer

The PC-3M Xenograft Rat Model Service for Prostate Cancer offers a robust, androgen receptor-negative metastatic platform that mirrors the aggressive dissemination and treatment-refractory behavior of castration-resistant prostatic malignancy. Alfa Cytology engineers each PC-3M engagement with exacting standards in cell authentication, surgical implantation, and longitudinal tumor monitoring, delivering reproducible growth curves and comprehensive histopathological endpoints that de-risk your preclinical therapeutic decisions from target validation through lead optimization.

Overview of PC-3M Xenograft Rat Model for Prostate Cancer

The PC-3M cell line was established from a xenografted tumor generated by inoculating the parental PC-3 human prostate carcinoma cells into nude mice, followed by serial passage and selection for enhanced metastatic capacity. Originating from a bone metastasis of a 62-year-old Caucasian male, the line retains the androgen receptor (AR)-negative, prostate-specific antigen (PSA)-negative phenotype characteristic of small cell neuroendocrine prostate carcinoma, rendering it independent of androgen signaling for proliferation. Genetically, PC-3M harbors a homozygous frameshift mutation in TP53 (p.Lys139Argfs*31), concomitant PTEN loss-of-function, and constitutive activation of the MAPK and PI3K-AKT pathways. These alterations drive rapid proliferation, matrix metalloproteinase-mediated invasion, and pronounced metastatic tropism toward lymph nodes, lung, and bone—making the model exceptionally suited for evaluating castration-resistant prostate cancer therapeutics, anti-metastatic agents, and novel targeted combinations.

Fig 1. PC-3M CRISPR screening experimental procedure, WT vs TKOV3 tumor growth curves, and sgRNA abundance distribution in primary tumors vs CTCs. (Xia, Fan, et al., 2022)

A distinctive metabolic feature of PC-3M is its elevated glutamine dependency relative to the parental PC-3 line. Proteomic and metabolomic profiling reveals that PC-3M cells exhibit three-fold greater glutamine uptake, channeling carbon skeletons into the citric acid cycle to fuel oxidative phosphorylation and biosynthetic demands associated with aggressive metastatic growth. This metabolic rewiring confers selective vulnerability to glutaminase 1 (GLS1) inhibitors such as CB-839, whose anti-proliferative effects are markedly more pronounced in PC-3M than in PC-3. Additionally, the line expresses nerve growth factor receptors and laminin-binding proteins that facilitate perineural invasion and stromal interactions, while its well-documented sublines—PC-3M-1E8 (highly metastatic) and PC-3M-2B4 (poorly metastatic)—provide an isogenic resource for dissecting the molecular determinants of prostate cancer dissemination.

Cell Line Information: PC-3M

The PC-3M human prostate carcinoma cell line represents one of the most aggressive and well-characterized metastatic variants in urologic oncology research. Derived through in vivo selection from the parental PC-3 line, PC-3M maintains a stable molecular identity and robust tumorigenic profile that supports reproducible xenograft development across immunodeficient rodent platforms. The table below enumerates the defining characteristics of this line.

Our Services

Alfa Cytology brings deep urologic oncology expertise to every PC-3M xenograft engagement, offering subcutaneous implantation with optional Matrigel basement membrane matrix for accelerated engraftment, paired with twice-weekly caliper monitoring, automated tumor volume calculation, and terminal histopathology. Our platform captures prostate cancer-specific endpoints including AR/PSA immunohistochemistry, Ki-67 proliferation indices, MMP1 expression quantification, and TUNEL apoptosis scoring, delivering audit-ready data packages that support your compound's progression from preclinical proof-of-concept toward IND-enabling toxicology.

Workflow of PC-3M Xenograft Rat Model Construction

Construction of a PC-3M prostate cancer xenograft demands meticulous cell culture stewardship, aseptic surgical technique, and standardized volumetric surveillance to ensure reproducible tumor growth and biologically meaningful therapeutic windows. The workflow below outlines the sequence employed to generate reliable PC-3M-bearing rat cohorts for preclinical evaluation.

1. Cell Line Resuscitation & Expansion. Cryopreserved PC-3M cells are thawed rapidly in a 37°C water bath and transferred to pre-warmed RPMI 1640 + 10% FBS supplemented with 0.1 mM MEM. Following centrifugation, cells are resuspended in complete medium. Identity is confirmed by STR profiling against the reference database, and mycoplasma negativity is verified by PCR. Cells are expanded to 70–80% confluence with >95% viability prior to inoculum preparation.
2. Recipient Animal Acclimation & Randomization. Immunodeficient recipient rats (athymic nude or SCID variants) are quarantined and acclimatized for a minimum of 7 days under controlled environmental conditions. Baseline body weights are recorded, and animals are randomized into treatment cohorts using stratified randomization based on body weight to minimize inter-group variance prior to tumor cell injection.
3. Inoculum Preparation & Viability Confirmation. PC-3M cells are harvested from exponential-phase cultures using 0.05% trypsin/EDTA, washed twice in sterile PBS, and resuspended at a concentration of 1–2.5 × 10⁷ cells/ml in ice-cold PBS. For enhanced engraftment, cells may be mixed 1:1 with reduced-growth-factor Matrigel basement membrane matrix. Cell viability is reconfirmed by trypan blue exclusion; only single-cell suspensions with >95% viability are approved for in vivo use.
4. Subcutaneous Tumor Cell Injection. Rats are briefly anesthetized with isoflurane inhalation (induction 3–4%, maintenance 1.5–2%). The right flank is shaved and disinfected with povidone-iodine and ethanol. A 25-gauge needle attached to a 1 mL syringe is used to inject 100–200 µL of cell suspension (delivering 2–5 × 10⁶ cells) into the subcutaneous space at the dorsal-lateral aspect of the flank. The injection site is inspected for leakage, and animals are returned to warmed recovery cages.
5. Post-Injection Monitoring & Supportive Care. Animals are observed for acute distress for 2 hours post-injection. Daily health checks include body weight, posture, hydration, and inspection of the injection site for ulceration, infection, or necrosis. Pre-emptive analgesia (buprenorphine 0.05 mg/kg subcutaneously every 8–12 hours for 48 hours) is provided per IACUC guidelines.
6. Longitudinal Tumor Surveillance. Tumor onset is monitored by palpation every 2–3 days beginning on day 7. Once tumors become palpable, two perpendicular diameters are measured with digital calipers twice weekly. Tumor volume is calculated using the modified ellipsoid formula (length × width² × 0.5). Animals are randomized into treatment arms once tumors reach 50–100 mm³, ensuring uniform baseline tumor burden across cohorts.
7. Endpoint Assessment & Comprehensive Harvest. Study endpoints are triggered by tumor volume reaching 2,000 mm³ (or institutional limit), ulceration, >20% body weight loss, or moribund condition. Under deep isoflurane anesthesia, animals are humanely euthanized. Tumors are excised, weighed, and bisected for fixation in 10% neutral-buffered formalin and snap-freezing in liquid nitrogen. Regional lymph nodes, lung, liver, and bone are collected for metastasis screening. Specimens undergo histopathology (H&E), immunohistochemistry (AR, PSA, Ki-67, MMP1, CD31), and molecular profiling of resistance mutations.

Fig 2. PC-3M Xenograft Rat Model construction workflow.

Case Study-PC-3M Xenograft Rat Model Development

In a recent preclinical engagement, Alfa Cytology established a subcutaneous PC-3M xenograft cohort in athymic nude rats to evaluate the anti-tumor activity of a novel glutaminase 1 (GLS1) inhibitor administered as monotherapy and in combination with docetaxel. Following flank implantation of 3 × 10⁶ viable PC-3M cells mixed with Matrigel, tumors were monitored by twice-weekly caliper measurements until reaching a mean volume of 80 mm³, at which point animals were randomized into vehicle, single-agent, and combination arms. The GLS1 inhibitor was administered orally twice daily, while docetaxel was delivered intravenously once weekly. Tumor growth curves revealed marked growth delay in the combination cohort relative to either monotherapy, with several animals exhibiting transient tumor regression. At study termination, excised tumors from the combination group showed reduced Ki-67 labeling index, increased cleaved caspase-3 positivity, and diminished glutamine-derived metabolite levels on metabolomic analysis. Pharmacokinetic sampling confirmed target plasma exposures for both agents, and ex vivo kinase profiling revealed suppression of mTOR signaling in treated tumors. These preclinical observations provided the sponsor with a robust efficacy signal and mechanistic rationale to advance the combination regimen toward formal GLP toxicology studies.

Why Choose Alfa Cytology?

Preclinical prostate cancer modeling demands more than tumor implantation—it requires an understanding of castration-resistant biology, metastatic evolution, and the metabolic dependencies that dictate therapeutic vulnerability. Alfa Cytology distinguishes its PC-3M service through the following specialized capabilities:

• Veterinary surgical team experienced in subcutaneous flank implantation with optional Matrigel supplementation, ensuring high tumor take rates, consistent growth kinetics, and minimal perioperative complications.
• Flexible model configurations encompassing wild-type PC-3M, PC-3M-1E8 high-metastatic derivatives, and luciferase-expressing variants to address efficacy, dissemination, and real-time tumor tracking objectives within a unified protocol.
• Comprehensive prostate cancer-focused histopathology suite delivering H&E, AR, PSA, Ki-67, MMP1, CD31, and TUNEL staining with digital image analysis for objective quantification of proliferation, apoptosis, angiogenesis, and invasion markers.
• Integrated metabolomics and molecular profiling capabilities including glutamine uptake assays, GLS1 activity measurement, and citric acid cycle metabolite quantification to capture metabolic drug effects unique to castration-resistant disease.
• Regulatory-compliant study execution under IACUC-approved protocols with full chain-of-custody documentation, GLP-capable data packages, and audit-ready reports designed to support IND submission and partnership discussions.
• Responsive scientific partnership with biweekly tumor volume reports, real-time data dashboards, and direct access to study directors for adaptive protocol amendments and rapid troubleshooting throughout the engagement.

Contact Us

Whether your prostate cancer program targets metabolic dependencies in castration-resistant disease, explores anti-metastatic strategies, or seeks to overcome chemoresistance through combination approaches, Alfa Cytology provides the preclinical infrastructure and urologic oncology expertise to move your candidate forward with confidence. Contact us today to discuss your PC-3M xenograft model requirements, and let our team design a study that generates the definitive preclinical evidence your development strategy demands.

For research use only. Not intended for any clinical use.